Cogent BiosciencesCOGT +3.32%25 Current Ratio is 15.14 as of Mar. 2026, which is 101% above its 10-year median of 7.54. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 1,417 Biotechnology companies, Cogent Biosciences ranks better than 86.87% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cogent Biosciences's current ratio for the quarter that ended in Mar. 2026 was 15.14.
Cogent Biosciences has a current ratio of 15.14. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cogent Biosciences's Current Ratio or its related term are showing as below:
COGT'
s Current Ratio Range Over the Past 10 Years
Min: 1.53 Med: 7.54 Max: 28.16
Current: 15.14
During the past 11 years, Cogent Biosciences's highest Current Ratio was 28.16. The lowest was 1.53. And the median was 7.54.
COGT's Current Ratio is ranked better than 86.87% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs COGT: 15.14
Cogent Biosciences (NAS:COGT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cogent Biosciences Current Ratio Related Terms
Cogent Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COGT vs SRRK, RYTM, PTCT: Current Ratio Comparison
For the Biotechnology subindustry, Cogent Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a Current Ratio of 15.14 as of Mar. 2026. This is 101% above median its historical median of 7.54. Over the past decade, Cogent Biosciences' Current Ratio has ranged from 1.53 to 28.16. According to the industry distribution chart, Cogent Biosciences ranks #186 out of 1417 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Cogent Biosciences' Current Ratio too high?
Cogent Biosciences' current Current Ratio of 15.14 is 101% above median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 28.16. The Biotechnology industry median Current Ratio is 3.89. Cogent Biosciences' value of 15.14 is 289.2% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #186 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Current Ratio compare to SRRK and RYTM?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #186 out of 1417 companies for Current Ratio. This places Cogent Biosciences in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Cogent Biosciences' value of 15.14 is 289.2% above this benchmark. Historically, Cogent Biosciences' own Current Ratio has ranged from 1.53 to 28.16 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 3.89, Cogent Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current Current Ratio of 15.14 is 289.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current Current Ratio is 15.14, which is 101% above median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Current Ratio of 15.14. The current Current Ratio is 15.14, which is 101% above median its 10-year median of 7.54 and 289.2% above the Biotechnology industry median of 3.89. Cogent Biosciences' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Current Ratio is 15.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score
Get the complete analysis for COGT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
